면역학 시장 규모, 점유율, 동향 분석 보고서 : 약물 계열별, 질환 적응증별, 유통 채널별, 지역별 및 부문별 예측(2026-2035년)

The global immunology market size was valued at USD 113.2 billion in 2025, and is projected to grow from USD 124.9 billion in 2026 to USD 299.3 billion in 2035, at a CAGR of 10.2% from 2026 to 2035. North America dominated the market, accounting for a revenue share of 50.0% in 2025. The global market encompasses therapeutics and biopharmaceutical products used to prevent, manage, and treat immune system-related disorders, including autoimmune diseases, inflammatory conditions, immunodeficiencies, and transplant rejection.

The pace of innovation in the immunology industry has accelerated significantly, driven by advancements in precision medicine, biologics, and targeted small-molecule therapies. A deeper understanding of immune system pathways and disease mechanisms has supported the development of Janus kinase (JAK) inhibitors, interleukin (IL) inhibitors, and other targeted immunomodulatory agents. Advancements in biomarkers, companion diagnostics, and molecular profiling are further enabling more precise patient stratification and treatment selection.

The growth is also driven by the increasing prevalence of autoimmune and chronic inflammatory disorders, the rising adoption of biologic therapies, and growing healthcare expenditure. Pharmaceutical and biotechnology companies are making substantial investments in clinical research, biosimilar development, and next-generation immunomodulatory therapies to expand treatment options and improve patient access. In addition, supportive regulatory pathways for innovative biologics, expanding specialty care infrastructure, and increasing availability of advanced treatment options are facilitating the commercialization and adoption of immunology therapeutics across major healthcare markets.

The market is expected to present significant growth opportunities due to continued investment in immunology research, advancements in biologics manufacturing, and the development of next-generation therapeutic modalities. Emerging approaches, including cell-based immunotherapies, next-generation monoclonal antibodies, bispecific antibodies, and artificial intelligence-enabled drug discovery, are expected to influence the future treatment landscape. However, high treatment costs, pricing pressures, biosimilar competition, and reimbursement challenges may affect market dynamics. Nevertheless, the growing demand for targeted and personalized therapies is expected to support the long-term expansion of the market.

Global Immunology Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities across each sub-segment from 2021 to 2035. For this study, Grand View Research has segmented the global immunology market report based on drug class, disease indication, distribution channel, and region:

• Drug Class Outlook (Revenue, USD Billion, 2021 - 2035)

Monoclonal Antibodies

Fusion Proteins

Immunosuppressants

Polyclonal Antibodies

Others

• Disease Indication Outlook (Revenue, USD Billion, 2021 - 2035)

Rheumatoid Arthritis

Psoriatic Arthritis

Plaque Psoriasis

Atopic Dermatitis

Inflammatory Bowel Disease

Others

• Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2035)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

• Regional Outlook (Revenue, USD Billion, 2021 - 2035)

North America

• U.S.
• Canada
• Mexico

Europe

• UK
• Germany
• France
• Italy
• Spain

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea

Central & South America

• Brazil
• Argentina

Middle East and Africa (MEA)

• South Africa
• Saudi Arabia
• UAE

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Methodology Segmentation & Scope
• 1.2. Market Definition
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Immunology Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
• 3.2. Industry Value Chain Analysis
• 3.3. Market Dynamics
  • 3.3.1. Market Driver Analysis
  • 3.3.2. Market Restraint Analysis
  • 3.3.3. Industry Opportunities
• 3.4. Immunology: Market Analysis Tools
  • 3.4.1. Industry Analysis - Porter's Five Forces Analysis
  • 3.4.2. PESTLE Analysis

Chapter 4. Immunology Market, Drug Class Analysis

• 4.1. Segment Dashboard
• 4.2. Immunology: Drug Class Movement Analysis, 2025 & 2035 (USD Billion)
• 4.3. Monoclonal Antibodies
  • 4.3.1. Monoclonal Antibodies Market Estimates and Forecasts, 2021 - 2035 (USD Billion)
• 4.4. Fusion Proteins
  • 4.4.1. Fusion Proteins Market Estimates and Forecasts, 2021 - 2035 (USD Billion)
• 4.5. Immunosuppressants
  • 4.5.1. Immunosuppressants Market Estimates and Forecasts, 2021 - 2035 (USD Billion)
• 4.6. Polyclonal Antibodies
  • 4.6.1. Polyclonal Antibodies Market Estimates and Forecasts, 2021 - 2035 (USD Billion)
• 4.7. Others
  • 4.7.1. Others Market Estimates and Forecasts, 2021 - 2035 (USD Billion)

Chapter 5. Immunology Market, Disease Indication Analysis

• 5.1. Segment Dashboard
• 5.2. Immunology: Disease Indication Movement Analysis, 2025 & 2035 (USD Billion)
• 5.3. Rheumatoid Arthritis
  • 5.3.1. Rheumatoid Arthritis Estimates and Forecasts, 2021 - 2035 (USD Billion)
• 5.4. Psoriatic Arthritis
  • 5.4.1. Psoriatic Arthritis Market Estimates and Forecasts, 2021 - 2035 (USD Billion)
• 5.5. Plaque Psoriasis
  • 5.5.1. Plaque Psoriasis Market Estimates and Forecasts, 2021 - 2035 (USD Billion)
• 5.6. Atopic Dermatitis
  • 5.6.1. Atopic Dermatitis Market Estimates and Forecasts, 2021 - 2035 (USD Billion)
• 5.7. Inflammatory Bowel Disease
  • 5.7.1. Inflammatory Bowel Disease Market Estimates and Forecasts, 2021 - 2035 (USD Billion)
• 5.8. Others
  • 5.8.1. Others Market Estimates and Forecasts, 2021 - 2035 (USD Billion)

Chapter 6. Immunology Market, Distribution Channel Analysis

• 6.1. Segment Dashboard
• 6.2. Immunology: Distribution Channel Movement Analysis, 2025 & 2035 (USD Billion)
• 6.3. Hospital Pharmacies
  • 6.3.1. Hospital Pharmacies Estimates and Forecasts, 2021 - 2035 (USD Billion)
• 6.4. Retail Pharmacies
  • 6.4.1. Retail Pharmacies Market Estimates and Forecasts, 2021 - 2035 (USD Billion)
• 6.5. Online Pharmacies
  • 6.5.1. Online Pharmacies Market Estimates and Forecasts, 2021 - 2035 (USD Billion)
• 6.6. Others
  • 6.6.1. Online Pharmacies Market Estimates and Forecasts, 2021 - 2035 (USD Billion)

Chapter 7. Immunology Market, Regional Analysis

• 7.1. Immunology Market Share by Region, 2025 & 2035
• 7.2. North America
  • 7.2.1. North America Immunology Market, 2021 - 2035 (USD Billion)
  • 7.2.2. U.S.
    • 7.2.2.1. U.S. Immunology Market, 2021 - 2035 (USD Billion)
    • 7.2.2.2. U.S. Immunology Market, By Drug Class, 2021 - 2035 (USD Billion)
    • 7.2.2.3. U.S. Immunology Market, By Disease Indication, 2021 - 2035 (USD Billion)
    • 7.2.2.4. U.S. Immunology Market, By Distribution Channel, 2021 - 2035 (USD Billion)
  • 7.2.3. Canada
    • 7.2.3.1. Canada Immunology Market, 2021 - 2035 (USD Billion)
    • 7.2.3.2. Canada Immunology Market, By Drug Class, 2021 - 2035 (USD Billion)
    • 7.2.3.3. Canada Immunology Market, By Disease Indication, 2021 - 2035 (USD Billion)
    • 7.2.3.4. Canada Immunology Market, By Distribution Channel, 2021 - 2035 (USD Billion)
  • 7.2.4. Mexico
    • 7.2.4.1. Mexico Immunology Market, 2021 - 2035 (USD Billion)
    • 7.2.4.2. Mexico Immunology Market, By Drug Class, 2021 - 2035 (USD Billion)
    • 7.2.4.3. Mexico Immunology Market, By Disease Indication, 2021 - 2035 (USD Billion)
    • 7.2.4.4. Mexico Immunology Market, By Distribution Channel, 2021 - 2035 (USD Billion)
• 7.3. Europe
  • 7.3.1. Europe Immunology Market, 2021 - 2035 (USD Billion)
  • 7.3.2. UK
    • 7.3.2.1. UK Immunology Market, 2021 - 2035 (USD Billion)
    • 7.3.2.2. UK Immunology Market, By Drug Class, 2021 - 2035 (USD Billion)
    • 7.3.2.3. UK Immunology Market, By Disease Indication, 2021 - 2035 (USD Billion)
    • 7.3.2.4. UK Immunology Market, By Distribution Channel, 2021 - 2035 (USD Billion)
  • 7.3.3. Germany
    • 7.3.3.1. Germany Immunology Market, 2021 - 2035 (USD Billion)
    • 7.3.3.2. Germany Immunology Market, By Drug Class, 2021 - 2035 (USD Billion)
    • 7.3.3.3. Germany Immunology Market, By Disease Indication, 2021 - 2035 (USD Billion)
    • 7.3.3.4. Germany Immunology Market, By Distribution Channel, 2021 - 2035 (USD Billion)
  • 7.3.4. France
    • 7.3.4.1. France Immunology Market, 2021 - 2035 (USD Billion)
    • 7.3.4.2. France Immunology Market, By Drug Class, 2021 - 2035 (USD Billion)
    • 7.3.4.3. France Immunology Market, By Disease Indication, 2021 - 2035 (USD Billion)
    • 7.3.4.4. France Immunology Market, By Distribution Channel, 2021 - 2035 (USD Billion)
  • 7.3.5. Italy
    • 7.3.5.1. Italy Immunology Market, 2021 - 2035 (USD Billion)
    • 7.3.5.2. Italy Immunology Market, By Drug Class, 2021 - 2035 (USD Billion)
    • 7.3.5.3. Italy Immunology Market, By Disease Indication, 2021 - 2035 (USD Billion)
    • 7.3.5.4. Italy Immunology Market, By Distribution Channel, 2021 - 2035 (USD Billion)
  • 7.3.6. Spain
    • 7.3.6.1. Spain Immunology Market, 2021 - 2035 (USD Billion)
    • 7.3.6.2. Spain Immunology Market, By Drug Class, 2021 - 2035 (USD Billion)
    • 7.3.6.3. Spain Immunology Market, By Disease Indication, 2021 - 2035 (USD Billion)
    • 7.3.6.4. Spain Immunology Market, By Distribution Channel, 2021 - 2035 (USD Billion)
• 7.4. Asia Pacific
  • 7.4.1. Japan
    • 7.4.1.1. Japan Immunology Market, 2021 - 2035 (USD Billion)
    • 7.4.1.2. Japan Immunology Market, By Drug Class, 2021 - 2035 (USD Billion)
    • 7.4.1.3. Japan Immunology Market, By Disease Indication, 2021 - 2035 (USD Billion)
    • 7.4.1.4. Japan Immunology Market, By Distribution Channel, 2021 - 2035 (USD Billion)
  • 7.4.2. China
    • 7.4.2.1. China Immunology Market, 2021 - 2035 (USD Billion)
    • 7.4.2.2. China Immunology Market, By Drug Class, 2021 - 2035 (USD Billion)
    • 7.4.2.3. China Immunology Market, By Disease Indication, 2021 - 2035 (USD Billion)
    • 7.4.2.4. China Immunology Market, By Distribution Channel, 2021 - 2035 (USD Billion)
  • 7.4.3. India
    • 7.4.3.1. India Immunology Market, 2021 - 2035 (USD Billion)
    • 7.4.3.2. India Immunology Market, By Drug Class, 2021 - 2035 (USD Billion)
    • 7.4.3.3. India Immunology Market, By Disease Indication, 2021 - 2035 (USD Billion)
    • 7.4.3.4. India Immunology Market, By Distribution Channel, 2021 - 2035 (USD Billion)
  • 7.4.4. Australia
    • 7.4.4.1. Australia Immunology Market, 2021 - 2035 (USD Billion)
    • 7.4.4.2. Australia Immunology Market, By Drug Class, 2021 - 2035 (USD Billion)
    • 7.4.4.3. Australia Immunology Market, By Disease Indication, 2021 - 2035 (USD Billion)
    • 7.4.4.4. Australia Immunology Market, By Distribution Channel, 2021 - 2035 (USD Billion)
  • 7.4.5. South Korea
    • 7.4.5.1. South Korea Immunology Market, 2021 - 2035 (USD Billion)
    • 7.4.5.2. South Korea Immunology Market, By Drug Class, 2021 - 2035 (USD Billion)
    • 7.4.5.3. South Korea Immunology Market, By Disease Indication, 2021 - 2035 (USD Billion)
    • 7.4.5.4. South Korea Immunology Market, By Distribution Channel, 2021 - 2035 (USD Billion)
• 7.5. Latin America
  • 7.5.1. Brazil
    • 7.5.1.1. Brazil Immunology Market, 2021 - 2035 (USD Billion)
    • 7.5.1.2. Brazil Immunology Market, By Drug Class, 2021 - 2035 (USD Billion)
    • 7.5.1.3. Brazil Immunology Market, By Disease Indication, 2021 - 2035 (USD Billion)
    • 7.5.1.4. Brazil Immunology Market, By Distribution Channel, 2021 - 2035 (USD Billion)
  • 7.5.2. Argentina
    • 7.5.2.1. Argentina Immunology Market, 2021 - 2035 (USD Billion)
    • 7.5.2.2. Argentina Immunology Market, By Drug Class, 2021 - 2035 (USD Billion)
    • 7.5.2.3. Argentina Immunology Market, By Disease Indication, 2021 - 2035 (USD Billion)
    • 7.5.2.4. Argentina Immunology Market, By Distribution Channel, 2021 - 2035 (USD Billion)
• 7.6. MEA
  • 7.6.1. South Africa
    • 7.6.1.1. South Africa Immunology Market, 2021 - 2035 (USD Billion)
    • 7.6.1.2. South Africa Immunology Market, By Drug Class, 2021 - 2035 (USD Billion)
    • 7.6.1.3. South Africa Immunology Market, By Disease Indication, 2021 - 2035 (USD Billion)
  • 7.6.2. Saudi Arabia
    • 7.6.2.1. Saudi Arabia Immunology Market, 2021 - 2035 (USD Billion)
    • 7.6.2.2. Saudi Arabia Immunology Market, By Drug Class, 2021 - 2035 (USD Billion)
    • 7.6.2.3. Saudi Arabia Immunology Market, By Disease Indication, 2021 - 2035 (USD Billion)
  • 7.6.3. UAE
    • 7.6.3.1. UAE Immunology Market, 2021 - 2035 (USD Billion)
    • 7.6.3.2. UAE Immunology Market, By Drug Class, 2021 - 2035 (USD Billion)
    • 7.6.3.3. UAE Immunology Market, By Disease Indication, 2021 - 2035 (USD Billion)
    • 7.6.3.4. UAE Immunology Market, By Distribution Channel, 2021 - 2035 (USD Billion)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company Categorization
• 8.3. Company Market Share Analysis, 2025
• 8.4. Strategy Mapping
  • 8.4.1. Expansion
  • 8.4.2. Mergers & Acquisition
  • 8.4.3. Partnerships & Collaborations
  • 8.4.4. New Product Launches
  • 8.4.5. Research And Development
• 8.5. Company Profiles
  • 8.5.1. AbbVie Inc
    • 8.5.1.1. Company Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. Johnson & Johnson
    • 8.5.2.1. Company Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Amgen Inc.
    • 8.5.3.1. Company Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. UCB S.A.
    • 8.5.4.1. Company Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Bristol Myers Squibb
    • 8.5.5.1. Company Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Novartis Ag
    • 8.5.6.1. Company Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Sanofi S.A.
    • 8.5.7.1. Company Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Eli Lilly and Company
    • 8.5.8.1. Company Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. Pfizer Inc
    • 8.5.9.1. Company Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. F. hoffman-La Roche Ltd
    • 8.5.10.1. Company Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic Initiatives